Stigma. What is it, and where does it come from? How do LGBTQ+ individuals, particularly those with HIV, experience it? How does stigma affect their mental health? What effect does it have on their engagement in HIV care? What do health care providers need to change to minimize stigma in their practices? These are some of the questions advanced practice nurse Dallas Ducar, CEO of Transhealth, discusses in this issue of eHIV Review. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Stigma. What is it, and where does it come from? How do LGBTQ+ individuals, particularly those with HIV, experience it? How does stigma affect their mental health? What effect does it have on their engagement in HIV care? What do health care providers need to change to minimize stigma in their practices? These are some of the questions advanced practice nurse Dallas Ducar, CEO of Transhealth, discusses in this issue of eHIV Review. Take our <a href="https://elit.dkbmed.com/issues/159/test" rel="noopener noreferrer nofollow" target="_blank">post-test</a> to claim CME credits.To read a companion newsletter <a href="https://elit.dkbmed.com/issues/156" rel="noopener noreferrer nofollow" target="_blank">click here</a>. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Stigma and HIV Care in LGBTQ+ Persons

Treatment-experienced patients with RAMs — resistance-associated mutations — remain a difficult management challenge. Every case of HIV drug resistance requires a therapeutic regimen individualized for each patient’s ART history. How will new and in-development agents affect the equation?Which drug combinations are right? Where does the balance between side effects and adherence lie?These are some of the questions Dr. Brian Wood from the Division of Allergy and Infectious Diseases at the University of Washington in Seattle addresses in this eHIV Review podcast.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Treatment-experienced patients with RAMs — resistance-associated mutations — remain a difficult management challenge. Every case of HIV drug resistance requires a therapeutic regimen individualized for each patient’s ART history. How will new and in-development agents affect the equation?Which drug combinations are right? Where does the balance between side effects and adherence lie?These are some of the questions Dr. Brian Wood from the Division of Allergy and Infectious Diseases at the University of Washington in Seattle addresses in this eHIV Review podcast.Take our <a href="https://elit.dkbmed.com/issues/153/test" rel="noopener noreferrer nofollow" target="_blank">post-test</a> to claim CME credits.To read a companion newsletter <a href="https://elit.dkbmed.com/issues/151" rel="noopener noreferrer nofollow" target="_blank">click here</a>. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Newer Options for Treatment-Experienced Patients Podcast

Most people living with HIV gain weight when initiating ART. For some, the weight gain signifies a “return to health”; for others, the additional weight can be clinically significant and may be strongly associated with an increased risk of metabolic abnormalities. What causes this weight gain? How can patients most at risk for weight-related comorbidities be identified? Join us as we discuss these and other issues with Dr. Todd Brown, Professor of Medicine and Epidemiology at Johns Hopkins University, in this eHIV Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Most people living with HIV gain weight when initiating ART. For some, the weight gain signifies a “return to health”; for others, the additional weight can be clinically significant and may be strongly associated with an increased risk of metabolic abnormalities. What causes this weight gain? How can patients most at risk for weight-related comorbidities be identified? Join us as we discuss these and other issues with Dr. Todd Brown, Professor of Medicine and Epidemiology at Johns Hopkins University, in this eHIV Review podcast. Take our <a href="https://elit.dkbmed.com/issues/149/test" rel="noopener noreferrer nofollow" target="_blank">post-test</a> to claim CME credits.To read a companion newsletter <a href="https://elit.dkbmed.com/issues/142" rel="noopener noreferrer nofollow" target="_blank">click here</a>. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Weight Gain in PLWH: A Clinical Concern

Are PLWH at higher risk for increased mortality from COVID-19 infection? How important is it for PWLH to get vaccinated and boosted? Is breakthrough COVID-19 infection more likely to occur among PLWH? What about “long COVID” (PASC)?Join Clinical Research Nurse Diane Kanjilal, manager of the Infectious Disease Clinical Research Unit at Massachusetts General Hospital, as we discuss these questions in this eHIV Review podcast.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Are PLWH at higher risk for increased mortality from COVID-19 infection? How important is it for PWLH to get vaccinated and boosted? Is breakthrough COVID-19 infection more likely to occur among PLWH? What about “long COVID” (PASC)?Join Clinical Research Nurse Diane Kanjilal, manager of the Infectious Disease Clinical Research Unit at Massachusetts General Hospital, as we discuss these questions in this eHIV Review podcast.Take our <a href="https://elit.dkbmed.com/issues/139/test" rel="noopener noreferrer nofollow" target="_blank">post-test</a> to claim CME credits.To read a companion newsletter <a href="https://elit.dkbmed.com/issues/135" rel="noopener noreferrer nofollow" target="_blank">click here</a>. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

COVID-19: The Morbidity/Mortality Risk

Long-acting injectable antiretroviral therapy is expected to improve adherence, reduce patient burden, and lower community viral load. But for which patients is it suitable? Can it be used as pre-exposure prophylaxis? How does the promise of long-acting ART actually mean in practice?Join us for this eHIV Review podcast, as Dr. Tanyaporn Wansom, Senior Infectious Diseases Consultant at Chayun Consulting in Bangkok Thailand, takes us to the clinic to answer some of these key questionsTake our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Long-acting injectable antiretroviral therapy is expected to improve adherence, reduce patient burden, and lower community viral load. But for which patients is it suitable? Can it be used as pre-exposure prophylaxis? How does the promise of long-acting ART actually mean in practice?Join us for this eHIV Review podcast, as Dr. Tanyaporn Wansom, Senior Infectious Diseases Consultant at Chayun Consulting in Bangkok Thailand, takes us to the clinic to answer some of these key questionsTake our <a href="https://elit.dkbmed.com/issues/133/test" rel="noopener noreferrer nofollow" target="_blank">post-test</a> to claim CME credits.To read a companion newsletter <a href="https://elit.dkbmed.com/issues/133" rel="noopener noreferrer nofollow" target="_blank">click here</a>. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Clinical Uses of LA Injectable ART

Twenty percent of new HIV diagnoses occur among adolescents and young adults. They’re a population underserved by HIV prevention resources, with lower retention in HIV care. Their awareness and uptake of PrEP has been and remains low. What can their clinicians do to more effectively help these vulnerable young people?  Join Dr. Luis Rubio from University of California San Francisco as we explore these and other important issues in this eHIV Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Twenty percent of new HIV diagnoses occur among adolescents and young adults. They’re a population underserved by HIV prevention resources, with lower retention in HIV care. Their awareness and uptake of PrEP has been and remains low. What can their clinicians do to more effectively help these vulnerable young people?  Join Dr. Luis Rubio from University of California San Francisco as we explore these and other important issues in this eHIV Review podcast. Take our <a href="https://elit.dkbmed.com/issues/130/test" rel="noopener noreferrer nofollow" target="_blank">post-test</a> to claim CME credits.To read a companion newsletter <a href="https://elit.dkbmed.com/issues/126" rel="noopener noreferrer nofollow" target="_blank">click here</a>. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Adolescents & Young Adults: Engaging the Vulnerable 20%

Rapid ART — initiating ART as soon as possible after an HIV diagnosis: How effective is it at bringing people with newly diagnosed HIV into lasting care? When and how should it be initiated? Are there particular populations where attempting rapid ART should be avoided?  Join us as we discuss these issues with Dr. Jonathan Colasanti from Atlanta’s Emory University and Grady Health System, in this eHIV Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Rapid ART — initiating ART as soon as possible after an HIV diagnosis: How effective is it at bringing people with newly diagnosed HIV into lasting care? When and how should it be initiated? Are there particular populations where attempting rapid ART should be avoided?  Join us as we discuss these issues with Dr. Jonathan Colasanti from Atlanta’s Emory University and Grady Health System, in this eHIV Review podcast. Take our <a href="https://elit.dkbmed.com/issues/122/test" rel="noopener noreferrer nofollow" target="_blank">post-test</a> to claim CME credits.To read a companion newsletter <a href="https://elit.dkbmed.com/issues/120" rel="noopener noreferrer nofollow" target="_blank">click here</a>. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Rapid ART: Benefits and Clinical Considerations

Undocumented LatinX immigrants are a special population facing many difficulties that hinder their engagement in HIV care and prevention. One obvious barrier is language: many undocumented immigrants do not understand either spoken or written English. Many may have never received routine medical care before and can be baffled by the complexities of the medical system. Insurance status and financial concerns are additional barriers. Finally, HIV-related stigma and fear of disclosure of their HIV and/or immigration status can prevent undocumented Latinx immigrants from engaging in HIV care and prevention.  How can clinicians most effectively help these individuals receive proper care? Join us as we find out, with Dr. Kathleen Page and nurse Owen Smith from Johns Hopkins University, in this eHIV Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Undocumented LatinX immigrants are a special population facing many difficulties that hinder their engagement in HIV care and prevention. One obvious barrier is language: many undocumented immigrants do not understand either spoken or written English. Many may have never received routine medical care before and can be baffled by the complexities of the medical system. Insurance status and financial concerns are additional barriers. Finally, HIV-related stigma and fear of disclosure of their HIV and/or immigration status can prevent undocumented Latinx immigrants from engaging in HIV care and prevention.  How can clinicians most effectively help these individuals receive proper care? Join us as we find out, with Dr. Kathleen Page and nurse Owen Smith from Johns Hopkins University, in this eHIV Review podcast. Take our <a href="https://elit.dkbmed.com/issues/114/test" rel="noopener noreferrer nofollow" target="_blank">post-test</a> to claim CME credits.To read a companion newsletter <a href="https://elit.dkbmed.com/issues/113" rel="noopener noreferrer nofollow" target="_blank">click here</a>. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Engaging Undocumented Latinx People In HIV Care

Better tolerability. More convenient dosing. Less serious side effects. Fewer potential drug-drug interactions. These are some of the most common reasons why individuals living with HIV want or need to change their currently successful ART regimens. But what do clinicians need to consider when determining which ART to switch to? What role do the patient’s comorbidities play in the selection process? How do changes in the patient’s condition not related to HIV affect the safety and efficacy of their current regimen? What does the evidence say? Join us in this eHIV Review podcast for a case-based discussion with Dr. Natasha Chida, from the Division of Infectious Diseases at the Johns Hopkins University School of Medicine, about these increasingly important issues. Claim CME/CEU credit: Critical Factors When Switching ART | DKBmed Hosted on Acast. See acast.com/privacy for more information.

Better tolerability. More convenient dosing. Less serious side effects. Fewer potential drug-drug interactions. These are some of the most common reasons why individuals living with HIV want or need to change their currently successful ART regimens. But what do clinicians need to consider when determining which ART to switch to? What role do the patient’s comorbidities play in the selection process? How do changes in the patient’s condition not related to HIV affect the safety and efficacy of their current regimen? What does the evidence say? Join us in this eHIV Review podcast for a case-based discussion with Dr. Natasha Chida, from the Division of Infectious Diseases at the Johns Hopkins University School of Medicine, about these increasingly important issues. Claim CME/CEU credit: <a href="https://elit.dkbmed.com/issues/112" rel="noopener noreferrer nofollow" target="_blank">Critical Factors When Switching ART | DKBmed</a> Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Critical Factors When Switching ART

Do antivirals increase weight gain? Does PrEP reduce the effect of gender-affirming hormone therapy in transgender women? Join us in the clinic with Dr. Sarah Puryear from the University of California San Francisco as we discuss these important questions. Take our post-test to claim CME credits. Hosted on Acast. See acast.com/privacy for more information.

Do antivirals increase weight gain? Does PrEP reduce the effect of gender-affirming hormone therapy in transgender women? Join us in the clinic with Dr. Sarah Puryear from the University of California San Francisco as we discuss these important questions. Take our <a href="https://elit.dkbmed.com/issues/110/test" rel="noopener noreferrer nofollow" target="_blank">post-test</a> to claim CME credits. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Weight Gain and Hormone Therapy

Expert insight and analysis providing information directly relevant to HIV care, through topic-focused newsletters summarizing the peer-reviewed literature and accompanying podcasts to illustrate how to apply that information in the clinic. Hosted on Acast. See acast.com/privacy for more information.

How can the emergency department become more effective in identifying acute HIV infection? What are the missed opportunities for screening? How can existing protocols be adapted to identify more patients with HIV infection without compromising clinicians’ ability to provide emergent care? Those are some of the questions we’re here to discuss today, with Dr. Douglas White and Dr. Erik Anderson from Highland Hospital’s Department of Emergency Medicine, part of the Alameda Health System in Oakland, California Hosted on Acast. See acast.com/privacy for more information.

How can the emergency department become more effective in identifying acute HIV infection? What are the missed opportunities for screening? How can existing protocols be adapted to identify more patients with HIV infection without compromising clinicians’ ability to provide emergent care? Those are some of the questions we’re here to discuss today, with Dr. Douglas White and Dr. Erik Anderson from Highland Hospital’s Department of Emergency Medicine, part of the Alameda Health System in Oakland, California Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Identifying HIV Infection in the ED

Nearly two of three new HIV infections in the United States appear in transgender women and men who have sex with men (MSM), with most transmission coming from people unaware of their infection. What should clinicians do to increase the rate of HIV screening in these populations to meet guideline recommendations? In this eHIV Review podcast, Dr. Robert Goldstein from Harvard Medical School and Massachusetts General Hospital takes us to the clinic to explain how HIV risk in these special populations can be identified and infection prevented. Take our post-test to claim CME credits. Hosted on Acast. See acast.com/privacy for more information.

Nearly two of three new HIV infections in the United States appear in transgender women and men who have sex with men (MSM), with most transmission coming from people unaware of their infection. What should clinicians do to increase the rate of HIV screening in these populations to meet guideline recommendations? In this eHIV Review podcast, Dr. Robert Goldstein from Harvard Medical School and Massachusetts General Hospital takes us to the clinic to explain how HIV risk in these special populations can be identified and infection prevented. Take our <a href="https://elit.dkbmed.com/issues/99/test" rel="noopener noreferrer nofollow" target="_blank">post-test</a> to claim CME credits. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Screening Strategies to Prevent HIV in MSM and Transgender Women

What do the currently published findings say about the effects of the COVID pandemic on people living with HIV? How is the pandemic affecting patients and clinicians in HIV care delivery and the health of people living with HIV?That’s the dual focus of this eHIV Review Special Edition issue. Matthew Spinelli, MD, MAS, assistant professor in the Division of HIV, ID, and Global Medicine at the University of California, San Francisco and San Francisco General Hospital, analyzes the current literature that addresses these questions, and then speaks directly with front-line clinicians about what they’re experiencing as they navigate a disrupted health care system. In addition to presenting his analysis of the data-driven evidence describing the effects of the COVID-19 virus on people with living with HIV, Dr. Spinelli also spoke directly with front-line clinicians to learn about what they’ve been experiencing as they work to maintain their patients’ health in this disrupted health care system. Take our post-test to claim CME credits. Hosted on Acast. See acast.com/privacy for more information.

What do the currently published findings say about the effects of the COVID pandemic on people living with HIV? How is the pandemic affecting patients and clinicians in HIV care delivery and the health of people living with HIV?That’s the dual focus of this eHIV Review Special Edition issue. Matthew Spinelli, MD, MAS, assistant professor in the Division of HIV, ID, and Global Medicine at the University of California, San Francisco and San Francisco General Hospital, analyzes the current literature that addresses these questions, and then speaks directly with front-line clinicians about what they’re experiencing as they navigate a disrupted health care system. In addition to presenting his analysis of the data-driven evidence describing the effects of the COVID-19 virus on people with living with HIV, Dr. Spinelli also spoke directly with front-line clinicians to learn about what they’ve been experiencing as they work to maintain their patients’ health in this disrupted health care system. Take our <a href="https://elit.dkbmed.com/issues/93/test" rel="noopener noreferrer nofollow" target="_blank">post-test</a> to claim CME credits. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

HIV and COVID-19: The Data and The Real World

What do the currently published findings say about the effects of the COVID pandemic on people living with HIV? How is the pandemic affecting patients and clinicians in HIV care delivery and the health of people living with HIV?That’s the dual focus of this eHIV Review Special Edition issue. Matthew Spinelli, MD, MAS, assistant professor in the Division of HIV, ID, and Global Medicine at the University of California, San Francisco and San Francisco General Hospital, analyzes the current literature that addresses these questions, and then speaks directly with front-line clinicians about what they’re experiencing as they navigate a disrupted health care system.  Hosted on Acast. See acast.com/privacy for more information.

What do the currently published findings say about the effects of the COVID pandemic on people living with HIV? How is the pandemic affecting patients and clinicians in HIV care delivery and the health of people living with HIV?That’s the dual focus of this eHIV Review Special Edition issue. Matthew Spinelli, MD, MAS, assistant professor in the Division of HIV, ID, and Global Medicine at the University of California, San Francisco and San Francisco General Hospital, analyzes the current literature that addresses these questions, and then speaks directly with front-line clinicians about what they’re experiencing as they navigate a disrupted health care system.  Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Immune Response in People with HIV

Challenges Supporting PLWH

Impact on HIV Treatment and Prevention Services

Case Study: HIV and COVID-19 Interaction

Clinical Presentations Among PLWH

Take our post-test to claim CME credits.To read a companion newsletter click here.Why do PWID — people who inject drugs — continue as an uncontrolled source of HIV infection? Where are the missed opportunities for increased screening in this population? What barriers have been identified and what strategies can successfully overcome them? Which harm reduction initiatives have been proved effective, and can they be cost-effectively replicated? In this eHIV Review podcast, Dr. Josh Barocas from the Boston University School of Medicine and Boston Medical Center, and Dr. Raagini Jawa, an infectious disease and addiction medicine fellow at Boston Medical Center, provide a clinical perspective on these important questions.  Hosted on Acast. See acast.com/privacy for more information.

Take our <a href="https://elit.dkbmed.com/issues/90/test" rel="noopener noreferrer nofollow" target="_blank">post-test</a> to claim CME credits.To read a companion newsletter <a href="https://elit.dkbmed.com/issues/85" rel="noopener noreferrer nofollow" target="_blank">click here</a>.Why do PWID — people who inject drugs — continue as an uncontrolled source of HIV infection? Where are the missed opportunities for increased screening in this population? What barriers have been identified and what strategies can successfully overcome them? Which harm reduction initiatives have been proved effective, and can they be cost-effectively replicated? In this eHIV Review podcast, Dr. Josh Barocas from the Boston University School of Medicine and Boston Medical Center, and Dr. Raagini Jawa, an infectious disease and addiction medicine fellow at Boston Medical Center, provide a clinical perspective on these important questions.  Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

Harm Reduction Strategies for People Who Inject Drugs

Take our post-test to claim CME credits.To read a companion newsletter click here.Both the on-going syphilis and HIV epidemics are highly concentrated among men who have sex with men. While PrEP has been proven to reduce HIV transmission, it is not designed to prevent sexually transmitted infections like gonorrhea, syphilis, and chlamydia. What does the evidence say about reducing STI risk in MSM, and how can it be most effectively applied in practice? In this podcast, Dr. Matthew Spinelli — Assistant Professor in the Division of HIV, ID, and Global Medicine at the University of California, San Francisco and San Francisco General Hospital — takes us to the clinic to explain what providers can do to help their patients avoid acquiring and transmitting STIs. Hosted on Acast. See acast.com/privacy for more information.

Take our <a href="https://elit.dkbmed.com/issues/82/test" rel="nofollow" target="_blank">post-test</a> to claim CME credits.To read a companion newsletter <a href="https://elit.dkbmed.com/issues/77" rel="noreferrer noopener nofollow" target="_blank">click here</a>.Both the on-going syphilis and HIV epidemics are highly concentrated among men who have sex with men. While PrEP has been proven to reduce HIV transmission, it is not designed to prevent sexually transmitted infections like gonorrhea, syphilis, and chlamydia. What does the evidence say about reducing STI risk in MSM, and how can it be most effectively applied in practice? In this podcast, Dr. Matthew Spinelli — Assistant Professor in the Division of HIV, ID, and Global Medicine at the University of California, San Francisco and San Francisco General Hospital — takes us to the clinic to explain what providers can do to help their patients avoid acquiring and transmitting STIs. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

PrEP, STIs, & Sexual Health Conversations

Expert insight and analysis providing information directly relevant to HIV care, through topic-focused newsletters summarizing the peer-reviewed literature and accompanying podcasts to illustrate how to apply that information in the clinic. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

eHIV Review

The best podcasts on investing. For anyone interested in the stories in the investing industry, whether it's an interview with Ray Dalio or Ed Thorp to the writer of The Big Short. This topic includes the most fascinating stories from all the best investors. Add episodes you're interested into your queue below!

Best Investing Podcasts

The best podcast episodes of the most interesting stories and things. From skyping someone while they're in space, to tracking down and meeting a telephone scammer in person, to the story of a Galapagos. These episodes will keep you and all your friends entertained and captivated for hours. Learn something new in every episode! Add episodes you're interested into your queue below!